Maintaining the Cold Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Maintaining the Cold Chain


Pharmaceutical Technology



Developing thermally controlled transportation (1)
Once testing is completed successfully, process implementation occurs. Provisions also should be made for training, quality assurance, maintenance of appropriate records for regulatory inspectors, and periodic reevaluation. The latter is necessary because "Even a qualified process is subject to change over time" (1).

Additional resources. Technical Report No. 39 also includes a list of references, a glossary of terms, an appendix describing International Conference on Harmonization (Geneva, Switzerland, http://www.ich.org/) and World Health Organization (Geneva, Switzerland, http://www.who.int/en/) stability tests, and an example of a study design for a refrigerated product. Finally, a sample transportation control strategy document outlines the effect of various temperature excursions on a particular product and advises whether it can still be used and to what degree the shelf life has been affected.

Regulators also continue to work on cold chain management. Health Canada (Ottawa, ON, Canada http://www.hc-sc.gc.ca/index_e.html) issued the final version of its guidance document, "Guidelines for Temperature Control of Drug Products during Storage and Transportation," in October 2005 (2). It contains specific recommendations for production transportation, containers, and container labeling.

Cold chain management tools

Drug makers have many options to help ensure temperature-sensitive products move through the supply chain under appropriate conditions, including time-temperature indicators, data loggers, radio frequency identification (RFID) technology, and insulated shippers and refrigerants. Several products and vendors have come to light since previous articles on this topic appeared (3, 4).

Pressure-sensitive temperature indicator labels integrate phase-change chemistry to irreversibly change color and provide a visual indication that thermal parameters have been exceeded. Customized designs can be set to thresholds from 0 to 200 C and are produced in an ISO-9001:2000-certified, FDA-registered facility. Labels can be supplied on rolls for automated application (Customized Irreversible temperature indicators, American Thermal Instruments, Inc., Beavercreek, OH, http://www.americanthermal.com/). The company also offers a stock-freeze indicator (Freeze√ Freeze Indicator).

A disposable, electronic temperature indicator, developed by a supplier of refrigerants and insulated shipping containers, reads "OK" if a shipment has not been temperature abused in transit. Each unit is programmed to the customer's time–temperature requirements and then tested to make sure it is reading accurately. The battery-powered unit weighs only 0.5 oz and can function as long as two years after activation. Double-sided tape affixes the indicator to the product being stored or shipped (KoolWatch electronic temperature indicator, Cold Chain Technologies, formerly FDC Packaging, Holliston, MA, http://www.coldchaintech.com/).

An advanced data-logging system incorporates monitoring and alarming software to provide deviations alerts. Rather than recording data at a single location like traditional monitoring systems, the software monitors temperature and humidity using data loggers arranged in a network throughout a shipment or site. The software connects to the independent data loggers and provides a centralized way to view the information. Distributing data-recording responsibilities among multiple sensors also enhances system reliability. If one sensor fails, others continue monitoring conditions (viewLinc Enterprise monitoring and alarming software, Veriteq, Richmond, BC, Canada, http://www.veriteq.com/).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here